While AMD3100 has been tested in preclinical models of lung fibrosis, its prophylactic antifibrotic activity was attributed to prevention of CXCL12-mediated migration of circulating fibrocytes into the injured lung. The gene discussed is CXCL12; the disease is pulmonary fibrosis.